Olanzapine for chemotherapy-induced nausea and vomiting: systematic review and meta-analysis
Fuente:
Redalyc
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Artículo científico |
| Sprache: | en |
| Veröffentlicht: |
Centro de investigaciones y Publicaciones Farmacéuticas
2017
|
| Schlagworte: | |
| Online-Zugang: | |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| _version_ | 1876467200045350912 |
|---|---|
| author | Legese Chelkeba |
| author_facet | Legese Chelkeba |
| contents | Olanzapine for chemotherapy-induced nausea and vomiting: systematic review and meta-analysis Legese Chelkeba Kidu Gidey Ayele Mamo Berhane Yohannes Tsehay Matso Tsegaye Melaku Medicina Drug Meta Nausea Vomiting Analysis as Topic Background: Chemotherapy induced nausea and vomiting (CINV) remains the most distressing event in patients receiving highly emetogenic chemotherapy (HEC) or moderately emetogenic chemotherapy (MEC).Objective: Therefore, this meta-analysis was conducted to evaluate the efficacy of olanzapine containing regimen in preventing acute, delayed and overall phases of CINV.Methods: PubMed, EBSCO, and Cochrane central register of controlled trials electronic databases were searched to identify RCTs that compared the effects of olanzapine with non-olanzapine regimen in preventing CINV. Randomized clinical trials (RCTs) that compared olanzapine containing regimen with non-olanzapine regimen were included. The primary outcomes were the percentage of patients achieving no vomiting or no nausea in acute, delayed and overall phases.Results: 13 RCTs that enrolled 1686 participants were included in this meta-analysis. 852 patients were assigned to olanzapine and 834 patients were assigned to non-olanzapine regimen (other standard antiemetic regimen). The percentages of no emesis achieved were 87.5%, 76.2%, 73.6% in olanzapine versus 76.7%, 61.8%, and 56.4% in non-olanzapine regimen in acute, delayed and overall phases, respectively. The percentages of no nausea were 82%, 64.3%, 61.6% in olanzapine group versus 71.3%, 41.8%, and 40.6% in non-olanzapine group in acute, delayed and overall phases, respectively. In general, olanzapine containing regimen achieved statistical superiority to non-olanzapine regimen in no vomiting endpoint in acute phase (OR 2.16; 95%CI 1.60 to 2.91, p<0.00001; I-square=5%; p=0.40), delayed phase (OR 2.28; 95%CI 1.1.46 to 3.54, p=0.0003; I-square=65%; p=0.001) and overall phase (OR 2.48; 95%CI 1.59 to 3.86, p<0.0001; I-square=69%; p< 0.0001).Conclusion: The current meta-analysis showed that olanzapine was statistically and clinically superior to non-olanzapine regimen in preventing CINV in most domains of the parameters. 2017 artículo científico 1885-642X https://www.redalyc.org/articulo.oa?id=69055066007 https://www.redalyc.org/journal/690/69055066007/ https://www.redalyc.org/journal/690/69055066007/html/ https://www.redalyc.org/journal/690/69055066007/69055066007.epub https://www.redalyc.org/journal/690/69055066007/movil 10.18549/PharmPract.2017.01.877 en http://www.redalyc.org/revista.oa?id=690 Pharmacy Practice application/pdf Centro de investigaciones y Publicaciones Farmacéuticas Pharmacy Practice (España) Num.1 Vol.15 |
| format | Artículo científico |
| id | redalyc_69055066007 |
| institution | Redalyc |
| language | en |
| publishDate | 2017 |
| publisher | Centro de investigaciones y Publicaciones Farmacéuticas |
| spellingShingle | Olanzapine for chemotherapy-induced nausea and vomiting: systematic review and meta-analysis Legese Chelkeba Medicina Drug Meta Nausea Vomiting Analysis as Topic Olanzapine for chemotherapy-induced nausea and vomiting: systematic review and meta-analysis Legese Chelkeba Kidu Gidey Ayele Mamo Berhane Yohannes Tsehay Matso Tsegaye Melaku Medicina Drug Meta Nausea Vomiting Analysis as Topic Background: Chemotherapy induced nausea and vomiting (CINV) remains the most distressing event in patients receiving highly emetogenic chemotherapy (HEC) or moderately emetogenic chemotherapy (MEC).Objective: Therefore, this meta-analysis was conducted to evaluate the efficacy of olanzapine containing regimen in preventing acute, delayed and overall phases of CINV.Methods: PubMed, EBSCO, and Cochrane central register of controlled trials electronic databases were searched to identify RCTs that compared the effects of olanzapine with non-olanzapine regimen in preventing CINV. Randomized clinical trials (RCTs) that compared olanzapine containing regimen with non-olanzapine regimen were included. The primary outcomes were the percentage of patients achieving no vomiting or no nausea in acute, delayed and overall phases.Results: 13 RCTs that enrolled 1686 participants were included in this meta-analysis. 852 patients were assigned to olanzapine and 834 patients were assigned to non-olanzapine regimen (other standard antiemetic regimen). The percentages of no emesis achieved were 87.5%, 76.2%, 73.6% in olanzapine versus 76.7%, 61.8%, and 56.4% in non-olanzapine regimen in acute, delayed and overall phases, respectively. The percentages of no nausea were 82%, 64.3%, 61.6% in olanzapine group versus 71.3%, 41.8%, and 40.6% in non-olanzapine group in acute, delayed and overall phases, respectively. In general, olanzapine containing regimen achieved statistical superiority to non-olanzapine regimen in no vomiting endpoint in acute phase (OR 2.16; 95%CI 1.60 to 2.91, p<0.00001; I-square=5%; p=0.40), delayed phase (OR 2.28; 95%CI 1.1.46 to 3.54, p=0.0003; I-square=65%; p=0.001) and overall phase (OR 2.48; 95%CI 1.59 to 3.86, p<0.0001; I-square=69%; p< 0.0001).Conclusion: The current meta-analysis showed that olanzapine was statistically and clinically superior to non-olanzapine regimen in preventing CINV in most domains of the parameters. 2017 artículo científico 1885-642X https://www.redalyc.org/articulo.oa?id=69055066007 https://www.redalyc.org/journal/690/69055066007/ https://www.redalyc.org/journal/690/69055066007/html/ https://www.redalyc.org/journal/690/69055066007/69055066007.epub https://www.redalyc.org/journal/690/69055066007/movil 10.18549/PharmPract.2017.01.877 en http://www.redalyc.org/revista.oa?id=690 Pharmacy Practice application/pdf Centro de investigaciones y Publicaciones Farmacéuticas Pharmacy Practice (España) Num.1 Vol.15 |
| title | Olanzapine for chemotherapy-induced nausea and vomiting: systematic review and meta-analysis |
| topic | Medicina Drug Meta Nausea Vomiting Analysis as Topic |
| url | https://www.redalyc.org/articulo.oa?id=69055066007 https://www.redalyc.org/journal/690/69055066007/ https://www.redalyc.org/journal/690/69055066007/html/ https://www.redalyc.org/journal/690/69055066007/69055066007.epub https://www.redalyc.org/journal/690/69055066007/movil |